TELEPRO: Patient‐Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

BACKGROUND. When carcinoid syndrome (CS) diarrhea (CSD) is inadequately controlled with long‐acting somatostatin analogs (SSAs), clinical practice guidelines recommend addition of the tryptophan hydroxylase inhibitor telotristat ethyl (TE). In a 12‐week multinational, randomized controlled trial, TE...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Strosberg, Jonathan, Joish, Vijay N., Giacalone, Susan, Perez‐Olle, Raul, Fish‐Steagall, Ann, Kapoor, Kanika, Dharba, Sam, Lapuerta, Pablo, Benson, Al B.
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2019
Sujets:
Endocrinology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853091/
https://ncbi.nlm.nih.gov/pubmed/31189618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0921
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires